Compare Cardinal Health Inc (CAH) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs T-Mobile Us Inc — how do they compare? Cardinal Health Inc trades at $228.48 (market cap $53.89B), while T-Mobile Us Inc trades at $188.49 (market cap $202.51B). The key difference: T-Mobile Us Inc is far larger — about 3.8× Cardinal Health Inc's market cap, and T-Mobile Us Inc pays the higher dividend (2.18%). Which is the better fit depends on your goals.
| CAH | TMUS | |
|---|---|---|
Market Cap | $53.89B | $202.51B |
Sector | Health | Media |
52-Week High | $239.71 | $259.01 |
52-Week Low | $146.04 | $167.65 |
Enterprise Value | $58.87B | $320.21B |
Dividend Yield | 0.89% | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
T-Mobile US (TMUS) trades at $188.42, up 0.43% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $88.31B and net income of $10.99B, though profit margins dipped slightly. Recent leadership changes and competitive threats from Starlink are in focus, while cash flow remains positive. The consensus price target is $243.09, implying significant upside.
Outlook remains positive given earnings beats and growth prospects, but risks include rising debt levels and satellite competition. Institutional sentiment is strongly bullish with 83% buy ratings, supporting a favorable risk-reward profile for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
